PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1424

Agree 100% rodad.

There is a wise saying - "Success breeds Success".

We have passed from the pre-clinical experimental phase into official Clinical Trials in canine lymphoma and MND with our very own formulated tablets.

Monepantel has performed well in the pre-clinical work, but institutional investors are not in business to fund experiments. They are looking for the key inflection point where PAA can finally announce either a commercial partnership for Phase 3 canine trials or a compelling case from FightMND to pursue expanded funded trials due to a strong positive outcome from our current Phase 1/2 MND trial.

When pen hits paper for either of these, then there will be a demand for PAA shares from the big players.

As Robert Bishop said at the AGM, "we are not GSK" with unlimited funds. Shareholders should all be aware of the long term strategy which is to introduce MPL against human cancers in clinical trials. This has been the desired goal since day one. Operational issues and financial constraints have seen timelines blow out but the endpoint remains the same and the rewards would make it a worthwhile wait.

I review my investment regularly and on balance I don't see any reason to exit at this point.

There's a lot of rumbling about inadequate messaging from the company. My opinion is that they are constrained by ASX rules as to what can be said without exaggeration as well as potential to breach confidentiality with potential partners if too much is revealed.

Good luck to all holders, Thrifty